A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1514-1520

  Harris, M ^a   Durakovic, C ^a   Rae, S ^a   Raboud, J ^a   Fransen, S ^a   Shillington, A ^a   Conway, B ^a   Montaner, J S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; NOCTURIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; RETREATMENT; TREATMENT FAILURE; VOMITING;

EID: 0031800832     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515317     Document Type: Article

References (15)

1. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine and zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
3. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
4. Cameron B, Heath-Chiozzi M, Kravcik S, Mills R, Pothoff A, Henry D. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract LB6a]. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.
5. 3 [abstract Mo B 294]. In: Program and abstracts: XI International Conference on AIDS (Vancouver). Vancouver: XI International Conference on AIDS Society, 1996:1.
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of an international panel. JAMA 1997;277:1962-9.
10. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
11. Montaner JSG, Hogg RS, O'Shaughnessy MV. Emerging international consensus for use of antiretroviral therapy. Lancet 1997;349:1042.
12. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstract 372]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
13. Murphy R, Gagnier P, Lamson M, Dusek A, Ju W, Hsu A. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients [abstract 374]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
14. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir and nevirapine [abstract 614]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
15. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile, and potential for clinical use. Expert Opin Invest Drugs 1996;5:1183-99.